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Abstract
Production processes for biopharmaceuticals with mammalian cells have to provide a 
nearly optimal environment to promote cell growth and product formation. Design and 
operation of a bioreactor are complex tasks, not only with respect to reactor configuration 
and size but also with respect to the mode of operation. New concepts for the design and 
layout of process strategies are required to meet regulatory demands and to guarantee 
efficient, safe, and reproducible biopharmaceutical production. Key elements are criti-
cal process parameters (CPPs), which affect critical quality attributes (CQAs), quality by 
design (QbD), process analytical tools (PAT), and design of experiment (DoE). In this 
chapter, some fundamentals including process and control strategies as well as concepts 
for process development are discussed. Examples for novel model-based concepts for the 
design of experiments to identify suitable fed-batch-feeding strategies are shown.
Keywords: cell culture, bioreactor, process strategy, design of experiment (DoE), kinetic 
model, quality by design
1. Introduction
The increasing demand for biopharmaceuticals in recent decades has led to diverse meth-
ods of process development and process establishment [1, 2]. Besides small molecules, bio-
pharmaceuticals are used for the medication of former untreatable diseases and provide a 
novel class of therapeutics. At the same time, applications such as personalized medicine are 
coming up [3]. The approvals of biopharmaceuticals produced with mammalian cells have 
increased from 33% in 1989 to 60% from 2010 to 2014. As shown in Figure 1, 30% of the 
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approved products in the USA were novel therapeutic antibodies, followed by hormones and 
blood-related medications.
The global biopharmaceuticals market was valued at approx. 160 US$ billion in 2014, and it 
is expected to grow with a compound annual growth rate of 9.6% from 2015 to 2020 [4]. In 
2013, 63 US$ billion sales were only generated from the three tumor necrosis factor (TNF)-
binding antibodies Humira® (adalimumab), Enbrel® (etanercept), and Remicade® (infliximab) 
[1]. According to BioPlan Association, 36% of the top 1000 biopharma companies are in North 
America followed by Europe with 24.3%. Seventeen percent are in Japan, China, and other 
Asian regions. Indian companies account for 7.6% and all unlisted regions (e.g., Russia and 
Latin-America) are under 4% each [5].
Trends for the future indicate a growing market of share up to 50% of the top 100 pharmaceu-
ticals to be bio-based [6]. At the same time, the costs for the development of biopharmaceutical 
drugs increased rapidly from 413 US$ billion (1980, year 2013 dollars) to 2558 US$ billion in 
2013 [7]. Reasons are the increasing regulatory restrictions due to a lack of transparency of 
pharma companies as well as cost-intensive drug development, preclinical, and clinical trials. 
The majority (approx. 70%) of recombinant protein therapeutics are produced nowadays in 
suspension Chinese hamster ovary (CHO) cell cultures. More than two decades of experience 
in the biopharmaceutical industry have demonstrated that CHO-cells do not only possess 
characteristics required for reproducible and efficient large-scale production of these drugs 
but can be regarded as safe for expressing drugs for human use [8, 9]. To ensure the safety of 
biological therapeutics, regulatory guidance requires adventitious agent testing of the bulk 
harvest [10].
Even if a novel pharmaceutical enters the market, selling prices in cost-conscious health-care 
systems are relatively low [11]. Due to variations in the quality of products in former times, 
the Food and Drug Administration (FDA) has moved from an end-product-based quality 
control (quality by inspection) with low restrictions concerning the production process to a 
Figure 1. Product approvals of biopharmaceuticals in the USA 2010–2014, data adapted from [1], others consists of 
miscellaneous products (e.g., bone morphogenetic proteins and fusion proteins).
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more defined process [quality by design (QbD)] with the incorporation of knowledge. In this 
chapter, fundamentals including process and control strategies as well as concepts for process 
development in the field of quality by design are discussed. Examples for novel model-based 
concepts for the design of experiments (DoEs) are shown.
2. The regulatory prospective: quality by design
Process harmonization for the production of biopharmaceuticals is driven forward by 
regulatory authorities and industrial companies. Therefore, the International Conference 
of Harmonization (ICH) was founded by regulatory authorities and industry associations 
of Japan, Europe, and the US. The World Health Organization (WHO) acts as a stand-
ing observer and helps to connect the regulatory authorities within the United Nations. 
Harmonization of regulatory requirements enables industry to reduce development times 
by removing the duplication of studies that was previously required to gain market approval 
for a new drug in each of the three regions. This directly affects the bottom line through 
reduced development times and regulatory review times. Therefore, these activities shall 
not only ensure the highest level of safety for production but also enhance the competitive 
position of those companies that choose to operate using its standards [12].
Reasons for the harmonization of biopharmaceuticals are the globalization of companies 
and the former diverse regulatory requirements to produce and sell biopharmaceuticals. 
Besides this, the development of robust bioprocesses to manufacture active, stable, and 
high-quality medicine with predefined quality attributes is still challenging. To harmo-
nize the requirements for biopharmaceutical production, the ICH quality guidelines ICH 
Q8 (R2), ICH Q9, and ICH Q10 introduced the concept of quality by design. This con-
cept includes quality-risk management systems and the implementation of Pharmaceutical 
Quality Systems [13–15].
The aim of quality by design is to guarantee a production process with high operational and 
process stability, in view of the product quality. Key elements are critical process parameters 
(CPP), which affect critical quality attributes (CQAs), and design of experiment (DoE). By 
combining these techniques, an efficient, safe, and reproducible biopharmaceutical produc-
tion process can be designed and will be approved from the regulatory authorities. Besides 
the implementation of good manufacturing practice (GMP) and environmental regulations, 
rigorous safety constraints need to be fulfilled. In addition, process analytical technologies 
(PAT) should be implemented to measure critical process parameters online and enhance a 
knowledge-based process design.
ICH Q8 describes the basic concepts for science and risk-based pharmaceutical manufactur-
ing process development and defines their minimal requirements. It is necessary to keep in 
mind that
“In all cases, the product should be designed to meet patients’ needs and the intended product 
performance.” [13].
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At first, the properties of the pharmaceutical with respect to quality need to be defined in 
the Quality Target Product Profile (QTPP). It contains all characteristics needed to guaran-
tee the quality, safety, and efficiency of the drug and taking, for example, the dosage form, 
dosage strengths, route of administration, dissolution, and different quality measures into 
account. It is the fundamental definition of the drug and essential for the process develop-
ment. Therefore, it should include all sources of prior knowledge, for example, literature, 
knowledge achieved during drug development, and experience within the companies. As 
an example, Goetze et al. [16] used attribute studies with clinical trial samples for a mAb 
treatment and described how information can be used to define the QTPP. After the QTPP 
of the drug is defined, quality attributes that have an effect on the product quality should be 
identified.
These properties, or critical quality attributes (CQAs), can be of “physical, chemical, biolog-
ical or microbiological” [13] origin and can change if the product and process knowledge 
increases. The CQAs should include the whole characteristic of the drug and is the basis 
of a robust manufacturing process development. Established quality attributes are the cell 
concentration during the cell culture production process, the product titer, aggregation, gly-
cosylation, and the sialylation grade [17, 18]. Afterwards, the production process is designed 
by using prior knowledge, initial experimental data, and quality-risk management methods 
(ICH Q9). In contrast to business and government areas, only few examples for the implemen-
tation of quality-risk management in the pharmaceutical industry were known in the past. 
The implementation of these methods, for example, failure mode effects analysis (FMEA), 
hazard operability analysis (HAZOP), and fault tree analysis (FTA), is described in the ICH 9 
Guideline to guarantee, that
“[…] product quality should be maintained throughout the product lifecycle such that the 
attributes that are important to the quality of the drug (medicinal) product remain consistent 
with those used in the clinical studies.” [14].
Quality-risk management methods offer a systematic approach to risk assessment, control, 
communication, and review during the product lifecycle. The aim is to iteratively increase the 
knowledge about the potential CQAs and the impact of variations on the quality of the drug 
product. After the identification of CQAs, process parameters and material attributes should 
be linked to each other to increase the process understanding. This should be done by using 
design of experiment methods and/or mathematical models and leads to the definition of the 
Design Space. The Design Space is the linkage of process parameters and input variables to 
the CQAs and their ranges, which do not affect the drug quality during manufacturing. The 
Design Space is defined in the regulatory approval and variations within the Design Space are 
not considered as a change in view of the regulators. Variations outside the Design Space are 
changes that need new regulatory approval. The main advantage of the Design Space is the 
flexibility of the manufacturing process in predefined ranges. Due to the deeper knowledge 
obtained during the risk assessment, the influence of variations is identified and evaluated. 
Afterwards, a control strategy is designed, based on the identification of CQAs and the defi-
nition of the Design Space. It should include how critical process parameters and material 
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attributes are controlled to ensure the product quality. Therefore, it can describe and evaluate 
how, for example, input materials, product specifications, unit operations in downstreaming, 
in-process testing, container closure systems, and/or intermediates can be controlled. This can 
result in less effort for end-product testing and real-time release of the drug. After a process 
is approved by the regulatory agencies, continuous improvement and product lifecycle man-
agement is recommended. Therefore, the ICH Q10 Guideline describes the implementation of 
pharmaceutical quality systems to
“[…] enhance the quality and availability of medicines around the world in the interest of 
public health.” [15].
It defines knowledge management, quality-risk management, and responsibilities of the com-
pany management to implement continuous improvement of the manufacturing process, 
product quality, and pharmaceutical quality system.
3. Requirements for process development
There is a rising demand for accelerated process development and increased efficiency and 
economics of production processes. Especially for the development of processes for biophar-
maceutical products, requirements for increased process understanding have evolved from 
the PAT and quality by design philosophy. Processes become more complex and sophisti-
cated, for example, by switching from simple batch to more complex fed-batch or continuous 
perfusion processes. The number of process variables that have to be monitored and their 
complexity has increased. Furthermore, the demands related to quality management and 
documentation (GMP) increased dramatically. A benefit of these higher efforts for develop-
ment is the increasing process knowledge. This can speed up technical transfer from devel-
opment into manufacturing, deliver a more optimized, robust process with higher titers and 
better reproducibility, and aid in troubleshooting and root-cause analysis of deviations dur-
ing production. In the following, this is described for the development of process and control 
strategies.
3.1. Process and control strategies
Batch and fed-batch-operated processes are predominantly used in the industry, although 
perfusion processes have been proven for certain applications to be of higher advantage, for 
example, when fragile and highly glycosylated products are involved [19–21]. In principle, the 
reactor content is supplemented with nutrients during fed-batch cultivations. The following 
challenges occur during the fed-batch cultivation of mammalian cell cultures [22]:
• Due to the exponential growth, the demand of nutrients and oxygen increases exponen-
tially, which can be challenging for the feed-control strategy.
• Changes in the metabolism of mammalian cells commonly occur during the course of a 
cultivation or between different cultivations.
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• Fed-batch-operated processes typically use feed(s) with high substrate concentrations, 
which lead to an increase of the production. Hence, inhibiting metabolites accumulate, 
especially when medium with high substrate concentrations is used.
• Only few cultivation parameters can be measured online during the process, making the 
design of the control strategy an even more challenging task.
• Process control at low substrate concentrations causes low levels of specific substrate 
uptake and metabolite production rates. This causes a decrease in cell growth and 
programmed cell death, that is, apoptosis due to substrate limitation or metabolite 
inhibition.
The main advantage of fed-batch operation, compared to batch mode, is the extension of the 
growth phase as well as the stationary phase, resulting in a higher cell and product concen-
tration and product yield. At the same time, choosing this operation mode leads to increased 
effort for the equipment and control. The optimization of fed-batch processes requires com-
plex knowledge regarding the composition of the feed and the operation of the feed flow. 
The latter commonly occurs without the use of additional data from the process (repeated 
fed-batch, constant feed, linear and exponential increase of feed flow). The determination of 
an adequate feed flow is mainly realized experimentally [22, 23]. Feeding strategies that use 
additional data from the process include bolus-feeding, that is, the substitution of substrate 
that was consumed in a given time interval, and proportional feeding, which is based on the 
oxygen uptake rate (OUR) [22, 24, 25].
4. Design of experiment as a powerful tool for process optimization
The development of complex biotechnological production processes in combination with ICH 
Guidelines is mostly done with approved design of experiment (DoE) methods. After a brief 
introduction, advantages and limitations of these methods will be discussed in the following 
part.
4.1. History of DoE
The concept for design of experiment was first introduced in 1926 by the statistician Ronald 
Fisher in the article “Field Experiments: How They Are Made and What They Are.” He pro-
posed the statistical planning and evaluation of field experiments in agriculture to determine 
the effect of treatments [26]. Therefore, he introduced randomization, replication, and block-
ing. The basic concept for using statistical methods is that the observations are normally dis-
tributed and drawn independently. The application of this assumption to real experimental 
settings was still limited in the 1920s. Therefore, Fisher proposed in 1923 the randomization 
of experiments in order to simulate independent-drawn sampling [27]. The main advantages 
are the elimination of influences from the experimenter to the experiment (selection bias) and 
the neglecting of external factors (accidental bias) [28].
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Replication is defined as the repetition of experiments with the same conditions to estimate 
the errors and variability. Although replication was known in the 1920s, Fisher demonstrated 
the need for it in the book “Statistical Methods for Research Workers,” which was published 
in 1925 [29]. He evaluated the treatment of 12 potato varieties with basal dressing and addi-
tional dressing of sulfur and chloride.
To test the significance, he split the field into two parts and took the standard deviations of the 
yield into account. The responses were not significant and no effect of additional sulfur and 
chloride was found [29]. Fisher arranged different lands in blocks with the same experimental 
conditions. By comparing the blocked experiments, he could reduce the error and increase the 
precision. After Fisher introduced the need for randomization, replication, and blocking, they 
were implemented by various authors and became state-of-the-art practice in experimental 
design [30–32].
In 1951, Box and Wilson adapted these techniques in the field of optimization of industrial 
settings and developed the response surface methodology (RSM) [33]. In contrast to Fishers 
field experiments, the response of a given technical setting can be determined quickly. By 
evaluating the response of the experiments, subsequent experiments can be designed. In par-
ticular, response surface methods are widely used because of their simple structure, inde-
pendence from underlying relationships, and the opportunities for optimization of factors in 
order to maximize a response [31, 34]. In the following years, these concepts were adapted by 
researches if less information about the underlying mechanisms are known.
4.2. DoE applied to QbD
In contrast to trial-and-error, or one-factor-at-a-time methods, statistical design of experiment (e.g., 
response surface) methods are widely used to develop biopharmaceutical processes [35–37]. They 
offer a tool to increase the process understanding and to identify the effect of process parameters 
to quality attributes. The main advantage of DoE methods is the systematic planning of efficient 
experiments in order to find relationships between factors and responses. Factors (e.g., medium 
components, feeding rates, and temperature) are the variables in the experimental design, which 
were defined previously by the experimenter and will be the input to a bioprocess.
The definition of boundary conditions for the factors is mainly based on heuristics and informa-
tion from literature. Subsequently, experiments are planned by DoE software algorithms and per-
formed in the laboratory. Then, the response (product titer and quality attributes) is determined 
and evaluated. Due to the high number of factors involved during bioprocesses, the identification 
of significant factors is performed by applying screening designs at first [38, 39]. In the context of 
designing biopharmaceutical production processes, they were used in the upstream as well as in 
the downstream part. As an example for the design of a bioprocess, Tai et al. [40] implemented 
a definite screening design in combination with an automated bioreactor system (250 mL) to 
identify the effect of 10 process parameters on the production of recombinant protein produced 
in Escherichia coli. Afterwards, the process parameters were optimized and recommendations for 
the Design Space of a pilot-scale plant (450 L) were given. As an example for the part of product 
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purification, Horvath et al. [41] used a screening design with eight experiments to determine the 
effect of different process parameters on the isoelectric point of a therapeutic antibody expressed 
in CHO cell culture. The pH, temperature, and the time of the temperature shift were significant. 
These factors were evaluated on three levels in a concluding response surface design to optimize 
the isoelectric point [41].
Due to the high number of parameters affecting the processes and the product quality, a variety 
of high-throughput platform technologies such as the Ambr (Sartorius), Ramos (Kuhner), and 
DASGIP (Eppendorf) were developed [42]. The advantage of DoE methods is the possibility 
to identify the effect of different factors by a reduced number of experiments. Based on the 
method used, even interactions between factors can be identified [31, 43]. Limitations occur 
with respect to the high number of experiments during process development and the reduction 
of complex relationships into simple linear correlations.
5. Modeling
The modeling of cell culture processes has been extensively discussed and summarized in the 
literature [43–46]. Mathematical models are used for the design, optimization, and control of 
cell culture processes. Established and simple model structures, like unstructured, unsegre-
gated, and empirical kinetic models, are state of the art [46, 47].
With the development of novel analytical methods, structured, segregated, and mechanistic 
models that allow a deeper comprehension on the mechanism of growth and production of 
mammalian cells proceed to take on greater significance [46]. It has been stressed by [48–50] 
that mathematical modeling is a substantial part of QbD since the model contributes to a 
scientific understanding on the product formation and the process control and monitoring. 
However, the performance of a model structure is highly dependent on the identification of 
key parameters. The main objective of a model is to find solutions by analyzing the model 
instead of performing various experiments. The model mainly works as an initial starting 
point to the obtainment of deeper process understanding that is required for process opti-
mization. Models are convenient if the reality can be described with sufficient accuracy of 
the real phenomena. For this purpose, the model structure should be kept as simple as pos-
sible with no unnecessary terms. According to Ref. [51], a model should be able to describe 
all phases of a cultivation with respect to the different operation modes (batch, fed-batch, 
etc.). At the same time, the parameters considered should have physical significance and 
should be determinable by simple experiments. Furthermore, it is favorable if models used 
for process optimization are applicable for a broad range of bioreactor scales [52, 53].
Due to the complexity of biological processes, simple models might be unsuitable for repre-
senting real phenomena. But even with complex models, the behavior of cells may change and 
predictions can differ from observed behavior. Reasons are the inadequate precision of the 
approximated model coefficients and the complexity during the determination of the model 
parameters. Therefore, a compromise between the accuracy of the model and the required 
experimental effort for the determination of the parameters needs to be agreed on for each 
application [54].
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6. Model-based design of experiment
The combination of model-based simulations with DoE methods for the development of cell 
culture processes is a novel tool for process development in context with QbD. As shown in 
Section 4, DoE methods are well established and state of the art for the optimization of process 
development, feeding, and media optimization. However, they can result in a high number of 
time-consuming and cost-intensive experiments. Even if high-throughput systems can handle 
these number of experiments in parallel, the heuristic restriction of boundaries and the high 
number of factors result in stepwise iterations with multiple runs.
The use of DoE methods for the optimization of feeding strategies is still limited, due to 
their complexity. Furthermore, narrowing the Design Space using only experimental meth-
ods requires plenty of time and experimental effort, especially in cases where a high num-
ber of relevant factors are targeted. Even if the experiments are planned and performed 
with much experience, several experimental runs can be expected [39]. In contrast to the 
chemical industry, process design based on mathematical models is not established in cell 
culture processes [50]. Reasons are the challenges of an appropriate application of models 
on complex metabolic pathways of mammalian cells regarding cell growth and product for-
mation. In addition, models targeting the metabolism of cell cultures demand more effort 
than those applied in chemical or microbial processes. Even if mathematical models are 
a promising tool for the development of stable processes that comply with the principles 
of QbD, examples have so far only been published in the field of product purification and 
polishing. In this way, Siegfried et al. [55] designed a blending unit using a discrete ele-
ment model. The flow characteristics of the blender used in production were predicted 
without performing lab-scale experiments. Rácz et al. [56] used model predictions to form 
a prognosis on the deviation of 12 chromatography columns that came from different lots 
of the same manufacturer. In Ref. [57], critical quality characteristics of a wet-granulation 
process were determined by population balance modeling and compared to experimental 
results. Even though the prediction of the resin’s porosity was of insufficient accuracy, the 
simulation allowed deeper understanding of the process, which leads to a more efficient 
determination of the Design Space. In the general procedure of process development, the 
use of complex, demanding, and time-consuming methods based on DoE tools has become 
common practice, although mathematical models are already used in the operation, con-
trol, and optimization of existing production processes [47, 58, 59]. Novel tools for pro-
cess development and optimization combine DoE tools with a growth model. As shown in 
Figure 2, their main objective is to increase the efficiency of DoE methods in context with 
QbD principles to identify critical process parameters, for example, fed-batch strategies or 
medium compositions [60, 61].
These methods are used to reduce the number of experiments during model-based DoE 
(mDoE) and the needed time for the development of more knowledge-based cell culture 
processes. In contrast to purely experimental or purely model-based methods, mathemati-
cal methods could be used to identify significant process variables in silico, which are later 
experimentally verified. In this way, a reduced number of experiments are planned by 
mDoE. The key element of an mDoE is the model, which compromise between the modeling 
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approach, the identification of the kinetic parameters, and the quality of the model regard-
ing the process. In contrast to process designs that are purely simulation-based and that 
involve highly complex models, which can deliver high-quality results, mDoE allows pro-
cess optimization with lower-model complexity. In this way, Sercinoglu et al. [60] developed 
a tool for the evaluation of feeding strategies during fed-batch cultivation of AGE1.hn cells. 
Therefore, a simple unstructured and unsegregated model was used to plan four fed-batch 
experiments.
Möller et al. [61] used a model to describe the dynamics of cell metabolism of CHO-XM-111 
cells in a two-step growth process with medium exchange followed by a fed-batch. Model 
parameters were fitted to averaged data from three parallel shake-flask cultivations, and 
model predictions were used to decrease the experimental space and the number of cultiva-
tion parameters in silico. To increase the total cell number (N) in a fed-batch, the l-glutamine 
concentration and constant feed rate were optimized by simulated DoE. Simulations were 
used to estimate the boundary conditions of the experimental DoE, starting with widely 
distributed data points. As shown in Figure 3, experiments were designed with the statistic 
software Design-Expert 9 (I optimality, five lack-of-fit, five replicate points). Each combina-
tion of the experimental design was simulated (MATLAB), and the maximum cell number 
(N) was calculated as a response and exported to generate response surface plots (Design-
Expert 9). The simulated data were treated in the same way as data from experiments. For 
this purpose, after transformation (power-transformation, lambda = −1) and analysis of 
Figure 2. Interaction of modeling, DoE, and experiments in mDoE.
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variance (ANOVA), an internal polynomial model was set up as a response surface for each 
iteration step (i) with a significance value α of 0.05.
Instead of performing multiple experiments to generate data for response surface plots, 
simulated data were used. In this way, a reduced experimental space for a concluding opti-
mization based on experiments was determined. One set of cultivation parameters in the 
range of the reduced experimental design was experimentally tested to evaluate the behav-
ior of CHO-XM-111 cells during medium exchange and fed-batch. As shown in Figure 4, 
the total cell number was predicted successfully during fed-batch and medium exchange.
The combination of model-based simulations with DoE is suitable for the generation of deeper 
understanding of processes, for example, the linkage of different process parameters to qual-
ity attributes. Furthermore, cultivation strategies for mammalian cell lines can be compared 
and evaluated before experiments have to be performed in the laboratory. This results in a 
significant reduction of the number of experiments required during process development 
and process establishment. The strategy is especially intended for the use in multi-single-use-
devices to speed up process development.
Figure 3. Workflow to decrease experimental space by model predictions (mDoE).
Model-Based Design of Process Strategies for Cell Culture Bioprocesses: State of the Art and New Perspectives
http://dx.doi.org/10.5772/67600
167
Author details
Johannes Möller and Ralf Pörtner
Address all correspondence to: poertner@tuhh.de
Institute of Bioprocess and Biosystems Engineering, Hamburg University of Technology, 
Hamburg, Germany
References
[1] Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol. 2014; 32(10): 992–1000. 
doi:10.1038/nbt.3040
[2] Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal anti-
body therapeutics. Nat Rev Drug Discov. 2010; 9(10): 767–774. doi:10.1038/nrd3229
[3] Ashley EA. Towards precision medicine. Nat Genet. 2016; 17: 507–552. doi:10.1038/
nrg.2016.86
[4] Global Biopharmaceuticals Market to Grow with CAGR of 9.6% to 2020 [Internet]. 2015. 
Available from: http://www.pharmexec.com/global-biopharmaceuticals-market-grow-
cagr-96-2020 [Accessed January 19, 2017]
[5] Concentration of Global Biopharmaceutical Manufacturing [Internet]. 2017. Available 
from: www.top1000Bio.com [Accessed January 18, 2017]
Figure 4. Comparison of predicted time course (line) and measured data (symbols) for an implemented process based 
on mDoE, cultivation performed in DASGIP SR0250ODSS bioreactor with marine-type-impeller, n = 150 rpm, T = 37°C, 
gassing with 0.1 vvm air and CO
2
 (5%), HP-1 and HP-5 = differently concentrated, chemically defined growth media 
(ChoMaster, Cell Culture Technologies, Switzerland), ME = Medium exchange, N = total cell number.
New Insights into Cell Culture Technology168
[6] Chen C, Le H, Goudar CT. Integration of systems biology in cell line and process 
development for biopharmaceutical manufacturing. Biochem Eng J. 2016; 107: 11–17. 
doi:10.1016/j.bej.2015.11.013
[7] DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new 
estimates of R&D costs. J Health Econ. 2016; 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012
[8] Jayapal KP, Wlaschin KF, HU WS, Yap M. Recombinant protein therapeutics from CHO 
cells-20 years and counting. Chem Eng Prog. 2007; 103: 40–47
[9] Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, 
Andersen MR, Neff N, Passarelli B, Koh W, Fan HC, Wang J, Gui Y, Lee KH, Betenbaugh 
MJ, Quake SR, Famili I, Palsson BO, Wang J. The genomic sequence of the Chinese 
Hamster Ovary (CHO) K1 cell line. Nat Biotechnol. 2011; 29: 735–741. doi:10.1038/
nbt.1932
[10] Berting A, Farcet MR, Kreil TR. Virus susceptibility of Chinese hamster ovary (CHO) 
cells and detection of viral contaminations by adventitious agent testing. Biotechnol 
Bioeng. 2010; 106: 598–607. doi:10.1002/bit.22723
[11] Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht 
AL. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. 
Nat Rev Drug Discov. 2010; 9(3): 203–214. doi:10.1038/nrd3078
[12] The Value and Benefits of ICH to Industry [Internet]. 2000. Available from: http://
www.ich.org/fileadmin/Public_Web_Site/ABOUT_ICH/Vision/Value_Benefits_for_
Industry_2000.pdf [Accessed January 19, 2017]
[13] ICH Q8. Pharmaceutical development Q8 (R2). ICH Harmonised Tripartite Guideline. 
2009. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf [Accessed August 28, 2016]
[14] ICH Q9. Quality risk management. ICH Harmonised Tripartite Guideline. 2009. 
Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf [Accessed August 28, 2016]
[15] ICH Q10. Pharmaceutical quality system Q10. ICH Harmonised Tripartite Guideline. 
2010. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf [Accessed August 28, 2016]
[16] Goetze AM, Schenauer MR, Flynn GC. Assessing monoclonal antibody product qual-
ity attribute criticality through clinical studies. mAbs. 2014; 2(5): 500–507. doi:10.4161/
mabs.2.5.12897
[17] Hossler P, Khattak SF, Li ZJ. Optimal and consistent protein glycosylation in mamma-
lian cell culture. Glycobiology. 2009; 19(9): 936–949. doi:10.1093/glycob/cwp079
[18] Gawlitzek M, Estacio M, Fürch T, Kiss R. Identification of cell culture conditions to con-
trol N-glycosylation site-occupancy of recombinant glycoproteins expressed in CHO 
cells. Biotechnol Bioeng. 2009; 103(6): 1164–1175. doi:10.1002/bit.22348
Model-Based Design of Process Strategies for Cell Culture Bioprocesses: State of the Art and New Perspectives
http://dx.doi.org/10.5772/67600
169
[19] Goldrick S, Ştefan A, Lovett D, Montague, G, Lennox, B. The development of an indus-
trial-scale fed-batch fermentation simulation. J Biotechnol. 2015; 193: 70–82. doi:10.1016/j.
jbiotec.2014.10.029
[20] Ozturk S, Hu WS, editors. Cell culture technology for pharmaceutical and cell-based 
therapies. CRC Press; 2005. ISBN 9780849351068
[21] Pollock J, Ho SV, Farid SS. Fed-batch and perfusion culture processes: economic, envi-
ronmental, and operational feasibility under uncertainty. Biotechnol Bioeng. 2013; 
110(1): 206–219. doi:10.1002/bit.24608
[22] Pörtner R, Schwabe JO, Frahm B. Evaluation of selected strategies for fed-batch cultures of 
a hybridoma cell line. Biotechnology Appl Bioc. 2004; 40: 47–55. doi:10.1042/BA20030168
[23] Wlaschin KF, HU WS. Fedbatch culture and dynamic nutrient feeding. In: Hu WS, 
Volume editor. Cell culture engineering. Springer; 2006. doi:10.1007/10_015
[24] Chen W, Graham C, Ciccarelli RB. Automated fed-batch fermentation with feed-back 
controls based on dissolved oxygen (DO) and pH for production of DNA vaccines. J Ind 
Microbiol Biotechnol. 1997; 18(1): 43–48. doi:10.1038/sj.jim.2900355
[25] Schwabe JO, Pörtner R, Märkl H. Improving an on-line feeding strategy for fed-batch 
cultures of hybridoma cells by dialysis and ‘Nutrient-Split’-feeding. Bioprocess Eng. 
1999; 20(6): 475–484. doi:10.1007/PL00009057
[26] Box JF. R.A. Fisher and the design of experiments, 1922–1926. Am Stat. 2012; 34(1): 1–7. 
doi:10.1080/00031305.1980.10482701
[27] Fisher RA, Mackenzie WA. Studies in crop variation. II. The manurial response of dif-
ferent potato varieties. J Argic Sci. 1923; 13(3): 311–320. doi:10.1017/S0021859600003592
[28] Efron B. Forcing a sequential experiment to be balanced. Biometrika. 1971; 58(3): 403–
417. doi:10.1093/biomet/58.3.403
[29] Fisher RA. Statistical methods for research workers. In: Kotz S, Johnson NL, edi-
tors. Breakthroughs in statistics: methodology and distribution. Springer; 1992. 
doi:10.1007/978-1-4612-4380-9_8
[30] Kirk RE. Experimental design. 1st ed. Wiley; 1982. doi:10.1002/0471264385.wei0201
[31] Montgomery DC. Design and analysis of experiments. 8th ed. Wiley; 2012. ISBN 
9780470128664
[32] Whitcomb PJ, Anderson MJ. RSM simplified: optimizing processes using response sur-
face methods for Design of Experiments. 1st ed. Taylor & Francis; 2004. ISBN 1563272970
[33] Box and Wilson. On the experimental attainment of optimum conditions. In: Kotz S, 
Johnson NL, editors. Breakthroughs in statistics: methodology and distribution. 1st ed. 
Springer; 1992. doi:10.1007/978-1-4612-4380-9_23
[34] Ayyub BM, McCuen RH. Probability, statistics, and reliability for engineers and scien-
tists, 3rd ed. CRC Press; 2016. ISBN 9781439809518
New Insights into Cell Culture Technology170
[35] Kalil SJ, Maugeri F, Rodrigues MI. Response surface analysis and simulation as a tool for 
bioprocess design and optimization. Process Biochem. 2000; 35(6): 539–550. doi:10.1016/
S0032-9592(99)00101-6
[36] Costa AC, Atala DIP, Maugeri F, Maciel R. Factorial design and simulation for the opti-
mization and determination of control structures for an extractive alcoholic fermenta-
tion. Process Biochem. 2001; 37(2): 125–137. doi:10.1016/S0032-9592(01)00188-1
[37] Parampalli A, Eskridge K, Smith L, Meagher M, Mowry M, Subramanian A. Development 
of serum-free media in CHO-DG44 cells using a central composite statistical design. 
Cytotechnology. 2007; 54(1): 57–68. doi:10.1007/s10616-007-9074-3
[38] Dubey KK, Behera BK. Statistical optimization of process variables for the production 
of an anticancer drug (colchicine derivatives) through fermentation: at scale-up level. N 
Biotechnol. 2011; 28(1): 79–85. doi:10.1016/j.nbt.2010.07.008
[39] Mandenius C, Brundin A. Bioprocess optimization using design-of-experiments meth-
odology. Biotechnol Prog. 2008; 24(6): 1191–1203. doi:10.1002/btpr.67
[40] Tai M, Ly A, Leung I, Nayar G. Efficient high-throughput biological process charac-
terization: definitive screening design with the ambr250 bioreactor system. Biotechnol 
Prog. 2015; 31(5): 1388–1395. doi:10.1002/btpr.2142
[41] Horvath B, Mun M, Laird MW. Characterization of a monoclonal antibody cell culture 
production process using a quality by design approach. Mol Biotechnol. 2010; 45(3): 
203–206. doi:10.1007/s12033-010-9267-4
[42] Royle KE, del Val IJ, Kontoravdi C. Integration of models and experimentation to opti-
mise the production of potential biotherapeutics. Drug Discov Today. 2013; 18(23–24): 
1250–1255. doi:10.1016/j.drudis.2013.07.002
[43] Pörtner R, Schäfer T. Modelling hybridoma cell growth and  metabolism: a compari-
son of selected models and data. J Biotechnol. 1996; 49(1–3): 119–135. doi:10.1016/ 
0168-1656(96)01535-0
[44] Eibl R, Eibl D, Pörtner R, Catapano G, Czermak P. Cell and tissue reaction engineering. 
1st ed. Springer; 2009. doi:10.1007/978-3-540-68182-3
[45] Tziampazis E, Sambanis A. Modeling of cell culture processes. Cytotechnology. 1994; 
14(3): 191–204. doi:10.1007/BF00749616
[46] Shirsat NP, English NJ, Glennon B, Al-Rubeai M. Modelling of mammalian cell cul-
tures. In: Al-Rubeai M, editor. Animal cell culture. Springer; 2015, pp. 259–326. 
doi:10.1007/978-3-319-10320-4_10
[47] Shirsat NP, Mohd A, Whelan J, English NJ, Glennon B, Al-Rubeai M. Revisiting Verhulst 
and Monod models: analysis of batch and fed-batch cultures. Cytotechnology. 2015; 
67(3): 515–530. doi:10.1007/s10616-014-9712-5
[48] Carrondo MJT, Alves PM, Carinhas N, Glassey J, Hesse F, Merten OW, Micheletti M, 
Noll T, Oliveira R, Reichl U, Staby A, Teixeira AP, Weichert H, Mandenius CF. How can 
Model-Based Design of Process Strategies for Cell Culture Bioprocesses: State of the Art and New Perspectives
http://dx.doi.org/10.5772/67600
171
measurement, monitoring, modeling and control advance cell culture in industrial bio-
technology? Biotechnol J. 2012; 7(12): 1522–1529. doi:10.1002/biot.201200226
[49] Kontoravdi C, Samsatli NJ, Shah N. Development and design of bio-pharmaceutical pro-
cesses. Curr Opin Chem Eng. 2013; 2(4): 435–441. doi:10.1016/j.coche.2013.09.007
[50] Ganguly J, Vogel G. Process Analytical Technology (PAT) and scalable automation for 
bioprocess control and monitoring-a case study. Pharm Eng. 2006; 32: 491–506.
[51] Caramihai M, Severi I. Bioprocess modeling and control. In: Matovic MD, editor. 
Biomass now: sustainable growth and use. 1st ed. InTech; 2013. doi:10.5772/2583
[52] Craven S, Shirsat N, Whelan J. Process model comparison and transferability across bio-
reactor scales and modes of operation for a mammalian cell bioprocess. Biotechnol Prog. 
2013; 29(1): 186–196. doi:10.1002/btpr.1664
[53] Berry B, Moretto J, Matthews T, Smelko J, Wiltberger K. Cross-scale predictive modeling 
of CHO cell culture growth and metabolites using Raman spectroscopy and multivariate 
analysis. Biotechnol Prog. 2015; 31(2): 566–577. doi:10.1002/btpr.2035
[54] Pörtner R, Platas OB, Frahm B, Hass, VC. Advanced process and control strategies for 
bioreactors. In: Larroche, C, Sanromán, MA, Du G, Pandey, A, editors. Current devel-
opments in biotechnology and bioengineering. 1st ed. Elsevier; 2017. pp. 463–493. 
doi:10.1016/B978-0-444-63663-8.00016-1
[55] Siegfried A, Daniele S, Charles R, Khinast JG. An integrated quality by design (QbD) 
approach towards design space definition of a blending unit operation by Discrete 
Element Method (DEM) simulation. Eur J Pharm Sci. 2011; 42(1–2): 106–115. doi:10.1016/j.
ejps.2010.10.013
[56] Rácz N, Kormány R, Fekete J, Molnár I. Establishing column batch repeatability accord-
ing to quality by design (QbD) principles using modeling software. J Pharmaceut 
Biomed. 2015; 108: 1–10. doi:10.1016/j.jpba.2015.01.037
[57] Chaudhury A, Barrasso D, Pandey P, Wu H, Ramachandran R. Population balance 
model development, validation, and prediction of CQAs of a high-shear wet granulation 
process: towards QbD in drug product pharmaceutical manufacturing. J Pharmaceut 
Innov. 2014; 9(1): 53–64. doi:10.1007/s12247-014-9172-7
[58] Rathore AS, Pathak M, Godara A. Process development in the QbD paradigm: role of 
process integration in process optimization for production of biotherapeutics. Biotechnol 
Prog. 2016; 32(2): 355–362. doi:10.1002/btpr.2209
[59] Fricke J, Pohlmann K, Jonescheit NA, Ellert A, Joksch B, Luttmann R. Designing a fully 
automated multi-bioreactor plant for fast DoE optimization of pharmaceutical protein 
production. Biotechnol J. 2013; 8(6): 738–747. doi:10.1002/biot.201200190
[60] Sercinoglu O, Platas Barradas O, Sandig V, Zeng AP, Pörtner R. DoE of fed-batch pro-
cesses: model-based design and experimental evaluation. BMC Proc. 2011; 5(8): 1–3. 
doi:10.1186/1753-6561-5-S8-P46
[61] Möller J, Eibl R, Eibl D, Pörtner R. Model-based DoE for feed batch cultivation of a CHO 
cell line. BMC Proc. 2015; 9(9): 1–2. doi:10.1186/1753-6561-9-S9-P42
New Insights into Cell Culture Technology172
